Optimizing treatment outcomes for patients with depression and generalized anxiety disorder.

Michael E. Thase, Madhukar Trivedi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The goal of the acute phase of pharmacotherapy of major depressive disorder or generalized anxiety disorder is remission (ie, complete resolution of symptoms) rather than simply a response (eg, at least a > or = 50% improvement in symptoms). Despite treatment, incompletely remitted patients often have persistent social and/or functional impairment, and are particularly vulnerable to relapse. To optimize outcomes, it is important to continue to adjust and refine the treatment plan until there is resolution of residual depressive symptoms and normalization of social functioning. Thereafter, prophylactic therapy is indicated to lessen the risk of recurrence and/or chronicity. Contemporary treatment options include older medications such as tricyclic antidepressants, newer compounds, such as selective serotonin reuptake inhibitors, the serotonin and norepinephrine reuptake inhibitor, venlafaxine, and a number of other medications with novel mechanisms of action. Although it has been conventional to assume that all antidepressants are equally effective, evidence from a recent pooled analysis of data from eight double-blind, randomized, controlled clinical studies suggests that venlafaxine therapy may be associated with higher remission rates.

Original languageEnglish (US)
Pages (from-to)93-102
Number of pages10
JournalPsychopharmacology Bulletin
Volume36 Suppl 2
StatePublished - Jun 2002

Fingerprint

Anxiety Disorders
Depression
Therapeutics
Recurrence
Tricyclic Antidepressive Agents
Major Depressive Disorder
Serotonin Uptake Inhibitors
Antidepressive Agents
Drug Therapy
Venlafaxine Hydrochloride

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Optimizing treatment outcomes for patients with depression and generalized anxiety disorder. / Thase, Michael E.; Trivedi, Madhukar.

In: Psychopharmacology Bulletin, Vol. 36 Suppl 2, 06.2002, p. 93-102.

Research output: Contribution to journalArticle

@article{bc141decf05841068ed84cc9f74de8fe,
title = "Optimizing treatment outcomes for patients with depression and generalized anxiety disorder.",
abstract = "The goal of the acute phase of pharmacotherapy of major depressive disorder or generalized anxiety disorder is remission (ie, complete resolution of symptoms) rather than simply a response (eg, at least a > or = 50{\%} improvement in symptoms). Despite treatment, incompletely remitted patients often have persistent social and/or functional impairment, and are particularly vulnerable to relapse. To optimize outcomes, it is important to continue to adjust and refine the treatment plan until there is resolution of residual depressive symptoms and normalization of social functioning. Thereafter, prophylactic therapy is indicated to lessen the risk of recurrence and/or chronicity. Contemporary treatment options include older medications such as tricyclic antidepressants, newer compounds, such as selective serotonin reuptake inhibitors, the serotonin and norepinephrine reuptake inhibitor, venlafaxine, and a number of other medications with novel mechanisms of action. Although it has been conventional to assume that all antidepressants are equally effective, evidence from a recent pooled analysis of data from eight double-blind, randomized, controlled clinical studies suggests that venlafaxine therapy may be associated with higher remission rates.",
author = "Thase, {Michael E.} and Madhukar Trivedi",
year = "2002",
month = "6",
language = "English (US)",
volume = "36 Suppl 2",
pages = "93--102",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",

}

TY - JOUR

T1 - Optimizing treatment outcomes for patients with depression and generalized anxiety disorder.

AU - Thase, Michael E.

AU - Trivedi, Madhukar

PY - 2002/6

Y1 - 2002/6

N2 - The goal of the acute phase of pharmacotherapy of major depressive disorder or generalized anxiety disorder is remission (ie, complete resolution of symptoms) rather than simply a response (eg, at least a > or = 50% improvement in symptoms). Despite treatment, incompletely remitted patients often have persistent social and/or functional impairment, and are particularly vulnerable to relapse. To optimize outcomes, it is important to continue to adjust and refine the treatment plan until there is resolution of residual depressive symptoms and normalization of social functioning. Thereafter, prophylactic therapy is indicated to lessen the risk of recurrence and/or chronicity. Contemporary treatment options include older medications such as tricyclic antidepressants, newer compounds, such as selective serotonin reuptake inhibitors, the serotonin and norepinephrine reuptake inhibitor, venlafaxine, and a number of other medications with novel mechanisms of action. Although it has been conventional to assume that all antidepressants are equally effective, evidence from a recent pooled analysis of data from eight double-blind, randomized, controlled clinical studies suggests that venlafaxine therapy may be associated with higher remission rates.

AB - The goal of the acute phase of pharmacotherapy of major depressive disorder or generalized anxiety disorder is remission (ie, complete resolution of symptoms) rather than simply a response (eg, at least a > or = 50% improvement in symptoms). Despite treatment, incompletely remitted patients often have persistent social and/or functional impairment, and are particularly vulnerable to relapse. To optimize outcomes, it is important to continue to adjust and refine the treatment plan until there is resolution of residual depressive symptoms and normalization of social functioning. Thereafter, prophylactic therapy is indicated to lessen the risk of recurrence and/or chronicity. Contemporary treatment options include older medications such as tricyclic antidepressants, newer compounds, such as selective serotonin reuptake inhibitors, the serotonin and norepinephrine reuptake inhibitor, venlafaxine, and a number of other medications with novel mechanisms of action. Although it has been conventional to assume that all antidepressants are equally effective, evidence from a recent pooled analysis of data from eight double-blind, randomized, controlled clinical studies suggests that venlafaxine therapy may be associated with higher remission rates.

UR - http://www.scopus.com/inward/record.url?scp=34547440342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547440342&partnerID=8YFLogxK

M3 - Article

C2 - 12490825

AN - SCOPUS:34547440342

VL - 36 Suppl 2

SP - 93

EP - 102

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

ER -